Bergen, Norway, 13 July 2017.
Reference is made to the stock exchange notice published by BerGenBio ASA (the
"Company") (OSE: BGBIO) on 27 June 2017 where the Company announced that the
board of directors of the Company had resolved to increase the Company's share
capital in connection with the exercise options pursuant to the Company's
employee share option program.The share capital increase has been duly
registered in the Norwegian Register of Business Enterprises. Following such
registration, the Company's share capital is NOK 4,975,720 divided into
49,757,200 shares, each with a nominal value of NOK 0.10.
For further information, please contact:
Richard Godfrey, Chief Executive Officer
Phone: +47 917 86 304
E-mail: media@bergenbio.com
About BerGenBio ASA
BerGenBio (Bergen, Norway) is a clinical-stage biopharmaceutical company focused
on developing a pipeline of first-in-class AXL kinase inhibitors to treat
multiple cancer indications. The Company is a world leader in understanding the
central role of AXL kinase in promoting cancer spread, immune evasion and drug
resistance in multiple aggressive haematological and solid cancers.
BGB324, is a selective, potent and orally available small molecule AXL inhibitor
in Phase II clinical development in four major cancer indications. It is the
only selective oral AXL inhibitor in clinical development. BGB324 is being
developed by BerGenBio as a single agent therapy in acute myeloid leukaemia
(AML)/myeloid dysplastic syndrome (MDS) and in combination with TARCEVA®
(erlotinib) in advanced non-small-cell lung cancer (NSCLC): and in combination
with KEYTRUDA® (pembrolizumab) in advanced NSCLC and triple negative breast
cancer (TNBC) in collaboration with MSD.
The Company is also developing a diversified pre-clinical pipeline of selective
AXL inhibitors including BGB149, anti-AXL monoclonal antibody.
For further information, please visit: www.bergenbio.com
This information is subject to the disclosure requirements pursuant to section 5
-12 of the Norwegian Securities Trading Act.